Cadila shares extend gains; up nearly 5%
Cadila Healthcare surged nearly 5 per cent today, extending its gains for the second session, after the company said the USFDA has inspected its Moraiya plant and found the unit complying with...17-02-2017
17-02-2017
Cadila shares extend gains; surge nearly 5%
USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms17-02-2017
Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 17, 2017, titled "Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray".17-02-2017
USFDA Inspection
Cadila Healthcare Ltd has informed BSE that the USFDA inspected Company's Moraiya facility from February 6, 2017 to February 15, 2017.At the end of the inspection, no observation (483) is issued.16-02-2017
Cadila Healthcare's Q3 net profit plunges 35% on subdued sales
Cadila Healthcare's third-quarter net profit declines after US sales dipped 17.2% year-on-year to Rs886.9 crore because of pricing pressure and regulatory issues at its Moraiya plant in Gujarat31-01-2017
Announces Q3 results (Standalone & Consolidated) & Limited Review Report (Standalone & Consolidated) for the Quarter ended December 31, 2016
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2016 The Unaudited Standalone results for the Quarter ended December 31, 2016:The Company has posted a net profit of Rs. 539 million for the quarter ended December 31, 2016 as compared to Rs. 4839 million for the quarter ended December 31, 2015. Total Income has decreased from Rs. 18146 million for the quarter ended December 31, 2015 to Rs....31-01-2017
Cadila Healthcare buys US-based Sentynl Therapeutics
Sentynl's acquisition marks Cadila's foray into the $8 billion specialty pain management drug market in the US20-01-2017
Zydus Cadila acquires Sentynl Therapeutics Inc., a US based specialty pharmaceutical company
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated January 19, 2017 titled 'Zydus Cadila acquires Sentynl Therapeutics Inc., a US based specialty pharmaceutical company'20-01-2017
Post results Conference Call with investors/analysts
Cadila Healthcare Ltd has informed BSE regarding "Post results Conference Call with investors/analysts".19-01-2017
Zydus Cadila open for buyouts in the US
Denies reports of looking to acquire Sentynl Therapeutics19-01-2017